Alembic Pharmaceuticals Limited
APLLTD.BO- 1D
- +0.7%
Alembic Pharmaceuticals Limited in brief
Alembic Pharmaceuticals Limited is a listed company in the Pharmaceutical industry, based in Vadodara, India. It was founded in 1907. Its market value was $2.2 B on 19 November 2026, which makes it the 6,005th largest listed company in the world and the 371st largest in India on this site. In the year to Mar 2022 it had sales of $664 M and a net profit of $68 M, about 10 cents of profit for every dollar of sales. It employs about 11,576 people. Its shares trade under the symbol APLLTD.BO (BSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Vadodara, Gujarat. The company manufactures and markets pharmaceutical products, including active pharmaceutical ingredients (APIs) and formulations, and has a presence in the macrolide anti-infective drug segment.
Alembic Pharmaceuticals produces formulations for therapeutic areas such as cardiology, dermatology, diabetes, ophthalmology, and infectious diseases for domestic and international markets. It operates manufacturing facilities in Gujarat (Panelav and Karakhadi), Sikkim, and Pithampur as well as research and development centres in India and the United States.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Alembic Pharmaceuticals Limited timeline
- 1907
- 🏁· approximateFounded
- 2011
- 📈Listed on National Stock Exchange of India as APLLTDFirst day of listing in the exchange's official list.
Events of Alembic Pharmaceuticals Limited from Wikidata and the exchanges' official lists. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Alembic Pharmaceuticals Limited share price · NSE (APLLTD.NS)
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Nov 19, 2026 | 1,044 | 1,054 | 1,039 | 1,050 | +0.5% | 333,407 |
| Nov 18, 2026 | 1,041 | 1,060 | 1,041 | 1,044 | -0.6% | 228,735 |
| Nov 17, 2026 | 1,058 | 1,062 | 1,045 | 1,051 | -0.6% | 201,850 |
| Nov 16, 2026 | 1,034 | 1,075 | 1,034 | 1,057 | +2.6% | 452,099 |
| Nov 13, 2026 | 1,049 | 1,073 | 1,024 | 1,030 | -1.6% | 422,868 |
| Nov 12, 2026 | 1,037 | 1,055 | 1,030 | 1,047 | +1.7% | 452,715 |
| Nov 11, 2026 | 1,023 | 1,052 | 1,021 | 1,030 | +1.2% | 540,258 |
| Nov 9, 2026 | 1,015 | 1,056 | 1,006 | 1,017 | +5.4% | 980,734 |
| Nov 6, 2026 | 894.80 | 985.00 | 890.00 | 965.15 | +8.0% | 2.4 M |
| Nov 5, 2026 | 919.70 | 936.95 | 885.60 | 893.50 | -1.5% | 1.9 M |
| Nov 4, 2026 | 808.00 | 963.35 | 803.65 | 906.70 | +12.9% | 4.2 M |
| Nov 3, 2026 | 803.00 | 814.85 | 798.50 | 802.80 | -0.0% | 92,294 |
| Nov 2, 2026 | 801.10 | 806.70 | 786.50 | 803.00 | +0.6% | 97,135 |
| Oct 30, 2026 | 794.85 | 800.00 | 784.05 | 797.85 | +0.4% | 72,865 |
| Oct 29, 2026 | 780.40 | 801.00 | 776.00 | 794.85 | +1.5% | 63,490 |
| Oct 28, 2026 | 769.95 | 788.00 | 765.90 | 782.80 | +2.1% | 125,417 |
| Oct 27, 2026 | 762.55 | 779.00 | 761.80 | 766.90 | +0.1% | 203,141 |
| Oct 26, 2026 | 759.45 | 769.55 | 753.55 | 766.40 | +0.8% | 43,824 |
| Oct 23, 2026 | 775.00 | 776.00 | 748.25 | 760.10 | -2.7% | 120,847 |
| Oct 22, 2026 | 779.00 | 786.95 | 777.15 | 781.30 | -0.8% | 45,524 |
| Oct 21, 2026 | 794.20 | 794.70 | 781.30 | 787.95 | -0.3% | 61,315 |
| Oct 19, 2026 | 790.05 | 799.00 | 779.00 | 790.35 | +0.1% | 137,411 |
| Oct 16, 2026 | 792.65 | 793.00 | 771.00 | 789.45 | -0.4% | 148,103 |
| Oct 15, 2026 | 797.95 | 802.40 | 789.25 | 792.65 | +0.0% | 77,862 |
| Oct 14, 2026 | 789.05 | 799.15 | 785.80 | 792.45 | -0.7% | 70,461 |
| Oct 13, 2026 | 787.10 | 800.00 | 778.85 | 797.85 | +1.1% | 70,432 |
| Oct 12, 2026 | 796.95 | 806.00 | 786.20 | 789.05 | -1.5% | 110,567 |
| Oct 9, 2026 | 801.00 | 806.20 | 788.75 | 800.95 | +0.1% | 187,843 |
| Oct 8, 2026 | 833.80 | 835.10 | 797.95 | 800.50 | -4.0% | 171,505 |
| Oct 7, 2026 | 834.10 | 839.00 | 821.25 | 833.80 | — | 135,889 |
Prices in INR from the National Stock Exchange of India; the last 30 trading days are listed, the chart shows up to ten years. For information only; not investment advice.
Alembic Pharmaceuticals Limited share price statistics
Changes compare closing prices; volatility is the annualised standard deviation of daily returns. Prices are as published by the exchange, not adjusted for splits, bonus issues or dividends. For information only; not investment advice.
Market cap history
World rank over time
Rank in India: #228 (Jan 2020) · #172 (Jan 2021) · #285 (Jan 2022) · #314 (Dec 2022) · #294 (Jul 2023) · #340 (Jan 2024) · #358 (Mar 2026) · #373 (Nov 2026) · #376 (Nov 2026) · #370 (Nov 2026) · #371 (Nov 2026) · #372 (Nov 2026) · #371 (Nov 2026)
Key ratios
- P/E ratio
- 32.5×
- Price / sales
- 3.3×
- Price / book
- 3.4×
- Free cash flow yield
- —
- Net margin
- 10.2%
- Operating margin
- —
- Return on equity
- 10.4%
- Liabilities / assets
- 26.5%
- Revenue per employee
- $57 K
- Profit per employee
- $6 K
Annual results
- Revenue
- $664 M
- Operating income
- —
- Net income
- $68 M
Mar-2022 ending year
Balance sheet
- Total assets
- $891 M
- Total liabilities
- $236 M
- Total equity
- $656 M
Mar-2022 ending year
Mutual funds holding Alembic Pharmaceuticals Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇮🇳 DSP Small Cap FundDSP Asset Managers | 1.50 M | $13 M | — | 0.59% | no change | Oct 31, 2026 |
| 🇮🇳 DSP Healthcare FundDSP Asset Managers | 1.44 M | $12 M | — | 3.1% | no change | Oct 31, 2026 |
| 🇮🇳 DSP ELSS Tax Saver FundDSP Asset Managers | 1.43 M | $12 M | — | 0.73% | no change | Oct 31, 2026 |
| 🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc. | 833,878 | $7 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇮🇳 DSP Aggressive Hybrid FundDSP Asset Managers | 799,463 | $7 M | — | 0.57% | no change | Oct 31, 2026 |
| 🇺🇸 Vanguard Emerging Markets Stock Index FundThe Vanguard Group, Inc. | 785,700 | $7 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Core MSCI Emerging Markets ETFBlackRock Fund Advisors | 765,673 | $6 M | — | <0.01% | +0.0% | May 31, 2026 |
| 🇺🇸 Emerging Markets Core Equity 2 PortfolioDimensional Fund Advisors LP | 478,490 | $4 M | — | 0.01% | −1.9% | Jul 31, 2026 |
| 🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc. | 219,611 | $2 M | — | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 The Emerging Markets Small Cap SeriesDimensional Fund Advisors LP | 186,858 | $2 M | — | 0.04% | no change | Jul 31, 2026 |
| 🇮🇳 DSP Multi Cap FundDSP Asset Managers | 127,660 | $1 M | — | 0.36% | no change | Oct 31, 2026 |
| 🇮🇳 DSP Equity Savings FundDSP Asset Managers | 99,017 | $1 M | — | 0.26% | no change | Oct 31, 2026 |
| 🇺🇸 WisdomTree India Earnings FundWisdomTree Asset Management, Inc. | 91,291 | $1 M | — | 0.04% | −5.6% | Jun 30, 2026 |
| 🇺🇸 iShares MSCI India Small-Cap ETFBlackRock Fund Advisors | 87,703 | $1 M | — | 0.11% | −8.3% | May 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Value FundDimensional Fund Advisors LP | 72,031 | $1 M | — | <0.01% | −11% | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Core Equity 2 ETFDimensional Fund Advisors LP | 65,097 | $1 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇮🇳 DSP Value FundDSP Asset Managers | 61,327 | $1 M | — | 0.21% | no change | Oct 31, 2026 |
| 🇺🇸 WisdomTree Emerging Markets SmallCap Dividend FundWisdomTree Asset Management, Inc. | 54,308 | $0 M | — | 0.03% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Avantis Emerging Markets Equity ETFAmerican Century ETF Trust | 58,537 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc. | 46,523 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 39,863 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street SPDR Portfolio Emerging Markets ETFSSGA Funds Management, Inc. | 38,157 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC | 37,302 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 29,904 | $0 M | — | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 20,502 | $0 M | — | <0.01% | −5.9% | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Social Core Equity PortfolioDimensional Fund Advisors LP | 19,489 | $0 M | — | <0.01% | −27% | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Core Equity Market ETFDimensional Fund Advisors LP | 17,475 | $0 M | — | <0.01% | −30% | Jul 31, 2026 |
| 🇺🇸 Strategic Advisers Emerging Markets FundStrategic Advisers LLC | 15,281 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares MSCI Emerging Markets Small-Cap ETFBlackRock Fund Advisors | 13,764 | $0 M | — | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Emerging Markets Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 9,666 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc. | 9,875 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Value ETFDimensional Fund Advisors LP | 8,679 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Emerging Asia Pacific ETFSSGA Funds Management, Inc. | 8,127 | $0 M | — | 0.02% | +7.7% | Jun 30, 2026 |
| 🇺🇸 Emerging Markets Targeted Value PortfolioDimensional Fund Advisors LP | 8,442 | $0 M | — | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc. | 7,522 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis Emerging Markets Equity FundAmerican Century ETF Trust | 8,197 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 7,407 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SA Emerging Markets Value FundFocus Advisor Solutions, LLC | 4,429 | $0 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Emerging Markets ex China Core Equity PortfolioDimensional Fund Advisors LP | 4,604 | $0 M | — | <0.01% | −56% | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets ex China Core Equity ETFDimensional Fund Advisors LP | 2,880 | $0 M | — | <0.01% | −1.1% | Jul 31, 2026 |
| 🇺🇸 Avantis Emerging Markets Small Cap Equity ETFAmerican Century ETF Trust | 3,096 | $0 M | — | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP | 2,525 | $0 M | — | <0.01% | +124% | Jul 31, 2026 |
| 🇺🇸 FlexShares Morningstar Emerging Markets Factor Tilt Index FundNorthern Trust Investments, Inc. | 2,000 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Sustainability Core 1 ETFDimensional Fund Advisors LP | 1,807 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis Emerging Markets ex-China Equity ETFAmerican Century ETF Trust | 285 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Oct 31, 2026. The 45 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Where Alembic Pharmaceuticals Limited operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for Alembic Pharmaceuticals Limited: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇳 India | Headquarters1 office | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
FDA drug approvals: Alembic Pharmaceuticals Limited#
16 approved applications held; 3 approvals and 0 new uses in 2013.
| Approved | Drug | Kind |
|---|---|---|
| 2013-05-28 | Metoprolol TartrateMetoprolol Tartrate · ANDA202871 | Generic drug (ANDA) |
| 2013-03-04 | DesvenlafaxineDesvenlafaxine · NDA204150 | New drug (NDA) |
| 2013-02-25 | Donepezil HydrochlorideDonepezil Hydrochloride · ANDA201724 | Generic drug (ANDA) |
| 2012-10-15 | IrbesartanIrbesartan · ANDA091236 | Generic drug (ANDA) |
| 2012-06-12 | Rivastigmine TartrateRivastigmine Tartrate · ANDA091689 | Generic drug (ANDA) |
| 2012-02-17 | Losartan Potassium And HydrochlorothiazideHydrochlorothiazide, Losartan Potassium · ANDA091617 | Generic drug (ANDA) |
| 2011-12-06 | Clonidine HydrochlorideClonidine Hydrochloride · ANDA091368 | Generic drug (ANDA) |
| 2011-11-21 | LeflunomideLeflunomide · ANDA091369 | Generic drug (ANDA) |
| 2011-01-13 | LamotrigineLamotrigine · ANDA090607 | Generic drug (ANDA) |
| 2010-12-14 | Venlafaxine HydrochlorideVenlafaxine Hydrochloride · ANDA078932 | Generic drug (ANDA) |
| 2010-11-30 | HydrochlorothiazideHydrochlorothiazide · ANDA200645 | Generic drug (ANDA) |
| 2010-10-06 | Losartan PotassiumLosartan Potassium · ANDA090428 | Generic drug (ANDA) |
| 2009-05-22 | FamotidineFamotidine · ANDA078916 | Generic drug (ANDA) |
| 2009-03-19 | Fluoxetine HydrochlorideFluoxetine Hydrochloride · ANDA090223 | Generic drug (ANDA) |
| 2009-03-13 | MetronidazoleMetronidazole · ANDA079067 | Generic drug (ANDA) |
| 2009-02-18 | MeprobamateMeprobamate · ANDA090122 | Generic drug (ANDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (ALEMBIC PHARMS LTD), so they follow acquisitions
Product recalls by Alembic Pharmaceuticals Limited#
9 recalls since 2015, 134,007 units in the notices that give a number. Drugs (FDA): 9.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Fesoterodine Fumarate, Extended-release Tablets, 8 mg, 30 Tablets, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-176-30Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.DrugsClass III | — | D-0248-2026 | |
| Fesoterodine Fumarate, Extended-release Tablets, 4 mg, 30-count bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-175-30Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.DrugsClass III | 4,884 | D-0156-2026 | |
| Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.DrugsClass II | 9,492 | D-0566-2025 | |
| Celecoxib Capsules, 200 mg, 500-count bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division), Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-142-71Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsuleDrugsClass II | 2,946 | D-0459-2025 | |
| Bromfenac Ophthalmic Solution 0.09%, 1.7 mL bottle, Rx only, Sterile, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, Manufactured by Alembic Pharmaceuticals Limitied, Gujarat, India, Made in India, NDC 62332-508-17Failed Impurities/Degradation SpecificationsDrugsClass II | — | D-0447-2025 | |
| Tobramycin Opthalmic Solution USP, 0.3%, 5mL bottle, Rx only, Manufactured for: Alembic Pharmaceuticals, Bedminster, NJ 07921, USA, NDC 62332-518-05Failed Impurities/Degradation SpecificationsDrugsClass III | 82,400 | D-1086-2023 | |
| Diclofenac Sodium Topical Solution USP, 2% w/w, 3.8 FL.OZ.(112 grams) bottles, Rx only, Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA Manufactured by: Alembic Pharmaceuticals Limited (Derma Division) Karakhadi, Vadodara 391450, India. NDC 62332-487-12Defective Delivery SystemDrugsClass II | 2,844 | D-0941-2023 | |
| Telmisartan Tablets, USP 20 mg, 30-count bottles, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division) Panelav 38935, Gujarat, India Manufactured for: Alembic Pharmaceuticals, Inc. 750 Route 202, Bridgewater, NJ 08807, NDC 62332-087-30Labeling: Label-mixupDrugsClass I | 12,288 | D-0326-2021 | |
| Aripiprazole Tablets, USP, 2 mg, 30 Tablets per bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division) Panelav 389350, Gujarat, India Manufactured for: Alembic Pharmaceuticals, Inc. 750 Route 202, Bridgewater, NJ 08807 USA, NDC 62332-097-30.Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.DrugsClass II | 19,153 | D-1341-2020 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
Discuss Alembic Pharmaceuticals Limited#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 45 funds hold $79 millionautomatic update · Oct 31, 2026
45 mutual funds in 2 countries hold shares of Alembic Pharmaceuticals Limited worth $79 million (funds' newest reports, up to 31 October 2026). Since their previous reports 4 funds added shares and 11 sold; on balance they sold $1 million. Share splits are not counted as trading.
How Alembic Pharmaceuticals Limited compares in Pharmaceutical
- Market cap$2.2 B · higher than 74% of 393
- Revenue$664 M · higher than 54% of 324
- Net margin10.2% · higher than 57% of 313
- P/E ratio32.5× · lower than 36% of 172
- Price / sales3.3× · lower than 39% of 219
- Price / book3.4× · lower than 33% of 207
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Alembic Pharmaceuticals Limited🇮🇳 | $2.2 B | 32.5× | 10.2% | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Nov 19, 2026
- Annual results:
- Mar-2022 ending year
- Balance sheet:
- Mar-2022 ending year
- Employees:
- As on March 2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, Wikipedia, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Alembic Pharmaceuticals Limited? Verify and update this profile — free
Show Alembic Pharmaceuticals Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.